Alkermes plc (8AK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alkermes plc (8AK) has a cash flow conversion efficiency ratio of -0.095x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-165.74 Million ≈ $-193.77 Million USD) by net assets (€1.75 Billion ≈ $2.05 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Alkermes plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Alkermes plc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Alkermes plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alkermes plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alkermes plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WG Tech JiangXi Co Ltd
SHG:603773
|
0.041x |
|
Shandong Xinchao Energy Co Ltd
SHG:600777
|
0.064x |
|
Shenzhen Zhongjin Lingnan Nonfemet Co Ltd
SHE:000060
|
0.005x |
|
Pampa Energia SA
BA:PAMP
|
-0.061x |
|
Shenzhen New Industries Biomedical
SHE:300832
|
0.069x |
|
Meritage Corporation
NYSE:MTH
|
-0.018x |
|
Scout24 AG
XETRA:G24
|
0.101x |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
-0.057x |
Annual Cash Flow Conversion Efficiency for Alkermes plc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Alkermes plc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 8AK market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €1.82 Billion ≈ $2.13 Billion |
€520.75 Million ≈ $608.82 Million |
0.286x | -4.51% |
| 2024-12-31 | €1.46 Billion ≈ $1.71 Billion |
€439.12 Million ≈ $513.38 Million |
0.300x | -10.18% |
| 2023-12-31 | €1.20 Billion ≈ $1.41 Billion |
€401.35 Million ≈ $469.22 Million |
0.334x | +1555.17% |
| 2022-12-31 | €1.04 Billion ≈ $1.22 Billion |
€21.04 Million ≈ $24.60 Million |
0.020x | -77.95% |
| 2021-12-31 | €1.11 Billion ≈ $1.30 Billion |
€101.72 Million ≈ $118.92 Million |
0.091x | +7.86% |
| 2018-12-31 | €1.17 Billion ≈ $1.37 Billion |
€99.28 Million ≈ $116.07 Million |
0.085x | +431.28% |
| 2017-12-31 | €1.20 Billion ≈ $1.41 Billion |
€19.19 Million ≈ $22.44 Million |
0.016x | +130.24% |
| 2016-12-31 | €1.21 Billion ≈ $1.41 Billion |
€-63.80 Million ≈ $-74.59 Million |
-0.053x | -71.78% |
| 2015-12-31 | €1.31 Billion ≈ $1.54 Billion |
€-40.36 Million ≈ $-47.19 Million |
-0.031x | -485.09% |
| 2014-12-31 | €1.40 Billion ≈ $1.63 Billion |
€11.14 Million ≈ $13.02 Million |
0.008x | -94.24% |
| 2013-12-31 | €1.07 Billion ≈ $1.25 Billion |
€147.53 Million ≈ $172.47 Million |
0.138x | -- |
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more